

FDA approves Dupixent for prurigo nodularis

October 3 2022



The U.S. Food and Drug Administration approved Dupixent

(dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.

Prurigo nodularis, a chronic, debilitating [skin disease](#) with underlying type 2 inflammation, is estimated to impact 75,000 U.S. adults and, until now, had no systemic treatment options.

The approval was based on priority review using data from two direct-to-phase 3 [trials](#) evaluating the efficacy and safety of Dupixent. In the two trials, more [patients](#) randomly assigned to Dupixent experienced a clinically meaningful reduction in itch from baseline to both 12 weeks (44 and 37 percent, respectively, versus 16 and 22 percent with [placebo](#)) and 24 weeks (60 and 58 percent, respectively, versus 18 and 20 percent for placebo). Compared with placebo (18 and 16 percent), more than twice as many Dupixent patients (48 and 45 percent) achieved clear or almost clear skin at 24 weeks. The safety profile was consistent with use of Dupixent for other dermatological conditions and included nasopharyngitis, conjunctivitis, herpes infection, dizziness, muscle pain, and diarrhea.

"Patients living with prurigo nodularis must often contend with dozens, if not hundreds, of itchy and painful nodules covering their body," George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron, said in a statement. "With this approval, those suffering with prurigo nodularis finally have a medicine to address the debilitating signs and symptoms of the disease."

More information: [Dupixent Approval](#)

Copyright © 2022 [HealthDay](#). All rights reserved.

Citation: FDA approves Dupixent for prurigo nodularis (2022, October 3) retrieved 11 July 2024 from <https://medicalxpress.com/news/2022-10-fda-dupixent-prurigo-nodularis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.